Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Research Methodology
Published in: BMC Medical Research Methodology 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research article

Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer’s disease with Fortasyn Connect

Authors: Floor M. van Oudenhoven, Sophie H.N. Swinkels, Tobias Hartmann, Hilkka Soininen, Anneke M.J. van Hees, Dimitris Rizopoulos

Published in: BMC Medical Research Methodology | Issue 1/2019

Login to get access

Abstract

Background

Many prodromal Alzheimer’s disease trials collect two types of data: the time until clinical diagnosis of dementia and longitudinal patient information. These data are often analysed separately, although they are strongly associated. By combining the longitudinal and survival data into a single statistical model, joint models can account for the dependencies between the two types of data.

Methods

We illustrate the major steps in a joint modelling approach, motivated by data from a prodromal Alzheimer’s disease study: the LipiDiDiet trial.

Results

By using joint models we are able to disentangle baseline confounding from the intervention effect and moreover, to investigate the association between longitudinal patient information and the time until clinical dementia diagnosis.

Conclusions

Joint models provide a valuable tool in the statistical analysis of clinical studies with longitudinal and survival data, such as in prodromal Alzheimer’s disease trials, and have several added values compared to separate analyses.
Appendix
Available only for authorised users
Literature
1.
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, et al.On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimer’s Res Ther. 2017; 9(1):60.CrossRef
2.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183–94.PubMedCrossRef
3.
Vaughan RM, Coen RF, Kenny R, Lawlor BA. Semantic and phonemic verbal fluency discrepancy in mild cognitive impairment: Potential predictor of progression to alzheimer’s disease. J Am Geriatr Soc. 2018; 66(4):755–9.PubMedCrossRef
4.
Munro CE, Donovan NJ, Amariglio RE, Papp KV, Marshall GA, Rentz DM, Pascual-Leone A, Sperling RA, Locascio JJ, Vannini P. The impact of awareness of and concern about memory performance on the prediction of progression from mild cognitive impairment to alzheimer disease dementia. Am J Geriatr Psychiatr. 2018; 26(8):896–904.CrossRef
5.
Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR. Addition of the A β42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying alzheimer’s disease dementia in mild cognitive impairment. Alzheimer’s Res Ther. 2018; 10(1):33.CrossRef
6.
Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997; 53(1):330–9.PubMedCrossRef
7.
Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000; 1(4):465–80.PubMedCrossRef
8.
Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Stat Sin. 2004; 14(3):809–34.
9.
Rizopoulos D. Joint Models for Longitudinal and Time-to-event Data: With Applications in R. Boca Raton: Chapman and Hall/CRC; 2012.CrossRef
10.
Sweeting MJ, Thompson SG. Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture. Biom J. 2011; 53(5):750–63.PubMedPubMedCentralCrossRef
11.
Prentice R. Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika. 1982; 69(2):331–42.CrossRef
12.
Dafni UG, Tsiatis AA. Evaluating surrogate markers of clinical outcome when measured with error. Biometrics. 1998; 54(4):1445–62.PubMedCrossRef
13.
Tsiatis AA, Davidian M. A semiparametric estimator for the proportional hazards model with longitudinal covariates measured with error. Biometrika. 2001; 88(2):447–58.CrossRef
14.
Li K, Luo S. Functional joint model for longitudinal and time-to-event data: an application to Alzheimer’s disease. Stat Med. 2017; 36(22):3560–72.PubMedPubMedCentralCrossRef
15.
Yu B, Ghosh P. Joint modeling for cognitive trajectory and risk of dementia in the presence of death. Biometrics. 2010; 66(1):294–300.PubMedCrossRef
16.
Dantan E, Joly P, Dartigues J-F, Jacqmin-Gadda H. Joint model with latent state for longitudinal and multistate data. Biostatistics. 2011; 12(4):723–36.PubMedCrossRef
17.
Proust-Lima C, Dartigues J-F, Jacqmin-Gadda H. Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach. Stat Med. 2016; 35(3):382–98.PubMedCrossRef
18.
19.
Ibrahim JG, Chen M-H, Sinha D. Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine trials. Stat Sin. 2004; 14(3):863–83.
20.
Crowther MJ, Lambert PC, Abrams KR. Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach. BMC Med Res Methodol. 2013; 13(1):146.PubMedPubMedCentralCrossRef
21.
Andrinopoulou E-R, Rizopoulos D, Jin R, Bogers AJ, Lesaffre E, Takkenberg JJ. An introduction to mixed models and joint modeling: analysis of valve function over time. Ann Thorac Surg. 2012; 93(6):1765–72.PubMedCrossRef
22.
Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T, Hallikainen I, Hallikainen M, Helisalmi S, et al.24-month intervention with a specific multinutrient in people with prodromal alzheimer’s disease (lipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017; 16(12):965–75.PubMedPubMedCentralCrossRef
23.
de Wilde MC, Vellas B, Girault E, Yavuz AC, Sijben JW. Lower brain and blood nutrient status in alzheimer’s disease: results from meta-analyses. Alzheimer’s Dement: Transl Res Clin Interv. 2017; 3(3):416–31.
24.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al.The diagnosis of dementia due to alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011; 7(3):263–9.CrossRef
25.
Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
26.
Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G. Longitudinal Data Analysis. Boca Raton: CRC press; 2008.CrossRef
27.
Brown ER, Ibrahim JG, DeGruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics. 2005; 61(1):64–73.PubMedCrossRef
28.
Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972; 34(2):187–202.
29.
Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer; 2006.
30.
Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2013.
31.
Tseng Y-K, Hsieh F, Wang J-L. Joint modelling of accelerated failure time and longitudinal data. Biometrika. 2005; 92(3):587–603.CrossRef
32.
Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw Online. 2010; 35(9):1–33.
Metadata
Title
Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer’s disease with Fortasyn Connect
Authors
Floor M. van Oudenhoven
Sophie H.N. Swinkels
Tobias Hartmann
Hilkka Soininen
Anneke M.J. van Hees
Dimitris Rizopoulos
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2019
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-019-0791-z

Other articles of this Issue 1/2019

BMC Medical Research Methodology 1/2019 Go to the issue

Research article

Evidence-based sizing of non-inferiority trials using decision models

Research article

Quality in perinatal care: applying performance measurement using joint commission on accreditation of healthcare organizations indicators in Italy

Research article

The Danish health and morbidity surveys: study design and participant characteristics

Research article

Robustness of the Tariff method for diagnosing verbal autopsies: impact of additional site data on the relationship between symptom and cause

Research article

Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting

Technical advance

“Spatial heterogeneity of environmental risk in randomized prevention trials: consequences and modeling”